Published • loading... • Updated
Shionogi Pays $2B to Acquire a Rare Disease Startup
The acquisition adds Aqneursa, approved for two inherited disorders, and lifts Shionogi’s rare-disease push after IntraBio reported $68 million in 2025 sales.
- On Monday, Shionogi & Co. agreed to acquire Austin, Texas-based IntraBio for $2 billion, gaining global rights to the rare disease therapy Aqneursa.
- This acquisition continues Shionogi's strategic shift to diversify beyond anti-infective drugs, building on its $2.5 billion purchase of the ALS treatment Radicava from Tanabe Pharma earlier this year.
- Aqneursa recently secured FDA approval for ataxia-telangiectasia, adding to its 2024 clearance for Niemann-Pick disease type C, a rare disorder impairing lipid movement within cells.
- Shionogi shares fell 4.5% Monday before recovering 3.8% Tuesday, with the transaction expected to close between November and December.
- CEO Isao Teshirogi stated the deal demonstrates a "solid commitment" to rare diseases, while the combined pipeline includes clinical-stage candidates for Pompe disease and Fragile X syndrome.
Insights by Ground AI
12 Articles
12 Articles
Japanese pharmacist Shionogi has agreed to buy the US-based IntraBio, a drug developer, for $2 billion. Exclusive material for subscribers. To have full access, access the material link and register.
·Rio de Janeiro, Brazil
Read Full Article
Coverage Details
Total News Sources12
Leaning Left0Leaning Right1Center4Last UpdatedBias Distribution80% Center
Bias Distribution
- 80% of the sources are Center
80% Center
C 80%
R 20%
Factuality
To view factuality data please Upgrade to Premium
